Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECP-1014 in Solid Tumors
NCT04930354Phase 1Unknown
- Sponsor
- Euclises Pharmaceuticals
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ECP-1014 in solid tumor, sponsored by Euclises Pharmaceuticals. Primary endpoint: Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
ECP-1014
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04930354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930354.